Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
Website: https://www.emergentbiosolutions.com/
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
574 articles about Emergent BioSolutions
-
Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
4/8/2022
Emergent BioSolutions Inc. will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for the second quarter of 2022, and financial outlook for full year 2022.
-
Emergent BioSolutions Provides Corporate Governance Update - Mar 23, 2022
3/23/2022
Emergent BioSolutions Inc. announced that its board of directors has undertaken a series of changes consistent with its commitment to continuous improvement of best practices for corporate governance.
-
Emergent BioSolutions to Participate in Investor Conferences - Mar 14, 2022
3/14/2022
Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following investor conferences.
-
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
-
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
3/11/2022
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatment being developed for known or suspected acute cyanide poisoning.
-
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
2/24/2022
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
2/7/2022
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for full year 2022, and revenue guidance for the first quarter of 2022.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Emergent BioSolutions, Vir Biotechnology and Thermo Fisher, come into 2022 with reports of new opportunities, new vaccines, and partnership expansions.
-
Founder and Executive Chairman of Emergent BioSolutions Announces RetirementFuad El-Hibri to Retire After More Than 20 Years
1/14/2022
Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1, 2022.
-
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
1/9/2022
Emergent BioSolutions Inc. announced its financial guidance for 2022 and selected preliminary unaudited financial results for 2021.
-
Drug Screening Market Size to Reach USD 13.56 Billion in 2027 Growing at a CAGR of 17.1%, according to Emergen Research
1/3/2022
According to Emergen Research, the global drug screening market size was USD 3.83 Billion in 2019 and is expected to reach USD 13.56 Billion in 2027 and register a revenue CAGR of 17.1% during the forecast period, 2020-2027.
-
Emergent BioSolutions is to Participate in Investor Conferences
1/3/2022
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2022.
-
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
12/16/2021
Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate.
-
Health Canada announces results of Emergent BioSolutions facility inspection
11/24/2021
Health Canada has completed its onsite inspection of the Emergent BioSolutions facility in Baltimore, Maryland . The European Medicines Agency and South African Health Products Regulatory Authority also participated in this inspection remotely.
-
Emergent BioSolutions Announces Stock Repurchase Program - Nov 11, 2021
11/11/2021
Emergent BioSolutions Inc. announced that its Board of Directors has authorized management to repurchase up to $250 million of the company's common stock from time to time on the open market or in privately negotiated transactions.
-
The U.S. government canceled a contract with Maryland-based Emergent BioSolutions, which earlier in the year ruined about 15 million doses of the Johnson & Johnson COVID-19 vaccine.
-
Emergent BioSolutions Reports Financial Results For Third Quarter 2021
11/4/2021
Emergent BioSolutions Inc. reported financial results for the third quarter ended September 30, 2021.
-
Emergent BioSolutions, the manufacturer responsible for the doses in question, is reportedly just waiting for the U.S. FDA's signal to start shipping the vaccines.
-
COVID-19 remains relentless in challenging the community as it continues to evolve. Here are some of the top news for the week.